KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Payables (2016 - 2025)

Historic Payables for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $679.5 million.

  • NovoCure's Payables rose 476.22% to $679.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $679.5 million, marking a year-over-year increase of 476.22%. This contributed to the annual value of $663.2 million for FY2024, which is 60265.81% up from last year.
  • As of Q3 2025, NovoCure's Payables stood at $679.5 million, which was up 476.22% from $663.5 million recorded in Q2 2025.
  • Over the past 5 years, NovoCure's Payables peaked at $679.5 million during Q3 2025, and registered a low of $52.7 million during Q1 2021.
  • In the last 5 years, NovoCure's Payables had a median value of $82.5 million in 2023 and averaged $230.3 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 328.62% in 2023, then soared by 71419.39% in 2024.
  • Quarter analysis of 5 years shows NovoCure's Payables stood at $72.6 million in 2021, then rose by 17.35% to $85.2 million in 2022, then grew by 10.79% to $94.4 million in 2023, then soared by 602.66% to $663.2 million in 2024, then grew by 2.46% to $679.5 million in 2025.
  • Its Payables was $679.5 million in Q3 2025, compared to $663.5 million in Q2 2025 and $654.1 million in Q1 2025.